



### Laboratory Investigation Report

Patient Name	: Mr. Mustafa Abdullah	Centre	:
Age/Gender	: 47 Y O M O D /M	OP/IP No/UHID	: //
MaxID/Lab ID	: SKMS.645554/3928102300229	Collection Date/Time	: 25/Oct/2023 04:15PM
Ref Doctor	: SELF	Reporting Date/Time	: 03/Nov/2023 10:03AM

#### Molecular Diagnostics



SIN No: B2B4339691

Test Name	Result	Unit	Bio Ref Interval
-----------	--------	------	------------------

#### BCR-ABL Kinase Domain(KD) Mutations IRMA, EDTA

PCR, Sequencing

BCR-ABL Kinase Domain(KD) Mutations IRMA	Not Detected
------------------------------------------	--------------

	THERAPY	CONTRAINDICATED MUTATIONS
BCR::ABL1 kinase domain contraindicated mutations based on NCCN GUIDELINES VERSION 1.2023	Asciminib	A337T or P465S
	Bosutinib	T315I, V299L, G250E, or F317L
	Dasatinib	T315I/A, F317L/V/I/C, or V299L
	Nilotinib	T315I, Y253H, E255K/V, or F359V/C/I
	Ponatinib, Omacetaxine, allogeneic HCT (CML-6), or clinical trial	None

#### NOTE :

1. This lab developed assay detects all point mutations in the BCR-ABL1 kinase domain spanning from amino acids 237 to 478. This assay does not detect variants in other parts of this gene.
2. Not Detected/Indeterminate result might be due to the presence of mutations below the detection limit of the assay i.e 20% VAF for Sanger sequencing.
3. Presence of PCR inhibitors in the sample may prevent DNA amplification.
4. All results should be interpreted in context of clinical findings.
5. Genetic counselling is recommended.

#### COMMENTS :

BCR-ABL1 kinase domain mutational analysis is helpful in the selection of subsequent TKI therapy for patients with inadequate initial response to first-line or second-line TKI therapy. Point mutations in the BCR-ABL1 kinase domain are a frequent mechanism of secondary resistance to TKI therapy and are associated with poor prognosis and higher risk of disease progression. Imatinib mesylate is a protein-tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase, the constitutively active tyrosine kinase created by the Philadelphia chromosome abnormality in CML. Patients with disease resistant to primary treatment with imatinib should be treated with bosutinib, dasatinib, or nilotinib in the second-line setting, taking into account BCR::ABL1 kinase domain mutation status.

Kindly correlate with clinical findings

\*\*\* End Of Report \*\*\*



Dr. Nitin Dayal, M.D.  
Principal Consultant & Head,  
Haematopathology



Dr Atul Thatai, Ph.D  
Director  
Molecular and Cyto Genomics

Test Performed at : 910 - Max Hospital - Saket M S S H, Press Enclave Road, Mandir Marg, Saket, New Delhi, Delhi 110017

Booking Centre : 4648 - Dr. Rohit Kapoor, House No. -100A/7, One Shop on Ground Floor, 8750033675

The authenticity of the report can be verified by scanning the Q R Code on top of the page

Page 1 of 1

Max Lab Limited (A Wholly Owned Subsidiary of Max Healthcare Institute Ltd.)

Max Super Speciality Hospital, Saket (West Block), 1, Press Enclave Road, Saket, New Delhi - 110 017, Phone: +91-11-6611 5050

(CIN No.: U85100DL2021PLC381826)

Helpline No. 7982 100 200 [www.maxlab.co.in](http://www.maxlab.co.in) [feedback@maxlab.co.in](mailto:feedback@maxlab.co.in)

**Conditions of Reporting:** 1. The tests are carried out in the lab with the presumption that the specimen belongs to the patient name as identified in the bill/test request form. 2. The test results relate specifically to the sample received in the lab and are presumed to have been generated and transported per specific instructions given by the physicians/laboratory. 3. The reported results are for the information and interpretation by the referring doctor only. 4. Some tests are referred to other laboratories to provide a wider test menu to the customer. 5. Max Healthcare shall in no event be liable for accidental damages loss, or destruction of specimen which is not attributable to any direct and mala fide act or omission of Max Healthcare or its employees. Liability of Max Healthcare for deficiency of services, or other errors and omissions shall be limited to fee paid by the patient for the relevant laboratory services.



MC-2714